OST-HER2 treated patients achieved 2-year overall survival compared with 40% in the historical control group (p = 0.0046)FDA ...

Smith Family Business Initiative at Cornell University, Family Enterprise USA, and The Roberts Group Survey Students in Family-owned Businesses ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated ...